AcelRx Pharmaceuticals (NASDAQ:ACRX) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Rating) in a report issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

AcelRx Pharmaceuticals Price Performance

Shares of NASDAQ ACRX opened at $0.71 on Thursday. The stock has a market capitalization of $5.29 million, a PE ratio of 0.11 and a beta of 0.27. The business has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $3.36. AcelRx Pharmaceuticals has a fifty-two week low of $0.61 and a fifty-two week high of $7.68.

Hedge Funds Weigh In On AcelRx Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. apricus wealth LLC raised its holdings in AcelRx Pharmaceuticals by 3.8% in the 3rd quarter. apricus wealth LLC now owns 135,500 shares of the specialty pharmaceutical company’s stock valued at $28,000 after acquiring an additional 5,000 shares in the last quarter. BlackRock Inc. raised its holdings in shares of AcelRx Pharmaceuticals by 1.0% during the 3rd quarter. BlackRock Inc. now owns 1,947,140 shares of the specialty pharmaceutical company’s stock worth $407,000 after buying an additional 19,986 shares in the last quarter. Values First Advisors Inc. raised its holdings in shares of AcelRx Pharmaceuticals by 3.5% during the 3rd quarter. Values First Advisors Inc. now owns 794,164 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 27,010 shares in the last quarter. Susquehanna International Group LLP acquired a new position in shares of AcelRx Pharmaceuticals during the 4th quarter worth $144,000. Finally, Virtu Financial LLC acquired a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter worth $29,000.

AcelRx Pharmaceuticals Company Profile

(Get Rating)

AcelRx Pharmaceuticals, Inc engages in the development and commercialization of therapies use in medically supervised settings. The firm’s portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.